Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. The three main types: Hepatitis A, B, ...

Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

A hospital is taking part in an initiative to try and help people who are unaware they’re living with blood-borne viruses ...

The Government has announced ‘significant’ changes to the childhood vaccination schedule, including a new routine appointment ...

New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that an ... favorable tolerability in a Phase ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Transmitted via bodily fluids, symptoms of hepatitis B include stomach aches ... boost – both of which deliver hepatitis B surface antigen (HBsAg) genes. In a clinical study of VTP-300, 67% of ...

A new report from Novotech, a leading global contract research organization, examines the global clinical trial landscape for Hepatitis B in 2025, offering valuable insights into novel therapies, ...